Skip to main content
Erschienen in: International Journal of Hematology 4/2019

08.02.2019 | Original Article

Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen

verfasst von: Takumi Hoshino, Satoru Takada, Nahoko Hatsumi, Toru Sakura

Erschienen in: International Journal of Hematology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Primary graft failure (PGF) is a lethal complication that occurs early after allogeneic stem cell transplantation (allo-SCT). Cord blood transplantation (CBT) is a potential re-transplantation option. Total body irradiation (TBI) is often incorporated into the pre-salvage CBT conditioning regimen following PGF; however, patients experiencing PGF are not always amenable to TBI, and non-TBI regimens for salvage CBT should be established. Here, we report five patients with hematologic malignancies who received salvage CBT for PGF following a non-TBI regimen using fludarabine (Flu), melphalan (Mel), and low-dose anti-thymocyte globulin (ATG). The median intervals between the failed allo-SCT and salvage CBT, as well as between the diagnosis of PGF and salvage CBT, were 37 days and 8 days, respectively. The median neutrophil recovery period was 21 days (range 18–21 days). Four of five patients achieved neutrophil engraftment following salvage CBT; all four exhibited sustained engraftment with complete donor chimerism. Three of the five patients were alive after a median follow-up time of 907 days (range 315–909 days) post-salvage CBT; two patients died of causes unrelated to recurrence. These data suggest that CBT following the non-TBI regimen described here is feasible in patients with PGF.
Literatur
1.
Zurück zum Zitat Schriber J, Agovi MA, Ho V, Ballen KK, Bacigalupo A, Lazarus HM, et al. Second unrelated donor hematopoietic cell transplantation for primary graft failure. Biol Blood Marrow Transpl. 2010;16:1099–106.CrossRef Schriber J, Agovi MA, Ho V, Ballen KK, Bacigalupo A, Lazarus HM, et al. Second unrelated donor hematopoietic cell transplantation for primary graft failure. Biol Blood Marrow Transpl. 2010;16:1099–106.CrossRef
2.
Zurück zum Zitat Waki F, Masuoka K, Fukuda T, Kanda Y, Nakamae M, Yakushijin K, et al. Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients. Biol Blood Marrow Transpl. 2011;17:841–51.CrossRef Waki F, Masuoka K, Fukuda T, Kanda Y, Nakamae M, Yakushijin K, et al. Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients. Biol Blood Marrow Transpl. 2011;17:841–51.CrossRef
3.
Zurück zum Zitat Fuji S, Nakamura F, Hatanaka K, Taniguchi S, Sato M, Mori S, et al. Peripheral blood as a preferable source of stem cells for salvage transplantation in patients with graft failure after cord blood transplantation: a retrospective analysis of the registry data of the Japanese Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transpl. 2012;18:1407–14.CrossRef Fuji S, Nakamura F, Hatanaka K, Taniguchi S, Sato M, Mori S, et al. Peripheral blood as a preferable source of stem cells for salvage transplantation in patients with graft failure after cord blood transplantation: a retrospective analysis of the registry data of the Japanese Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transpl. 2012;18:1407–14.CrossRef
4.
Zurück zum Zitat Yoshihara S, Ikegame K, Taniguchi K, Kaida K, Kim EH, Nakata J, et al. Salvage haploidentical transplantation for graft failure using reduced-intensity conditioning. Bone Marrow Transpl. 2012;47:369–73.CrossRef Yoshihara S, Ikegame K, Taniguchi K, Kaida K, Kim EH, Nakata J, et al. Salvage haploidentical transplantation for graft failure using reduced-intensity conditioning. Bone Marrow Transpl. 2012;47:369–73.CrossRef
5.
Zurück zum Zitat Ishiyama K, Takeda J, Kondo T, Sugimoto N, Kawabata H, Kitano T, et al. Feasibility of salvage cord blood transplantation following fludarabine, melphalan and low-dose TBI for graft rejection after hematopoietic stem cell transplantation. Bone Marrow Transpl. 2016;51:985–7.CrossRef Ishiyama K, Takeda J, Kondo T, Sugimoto N, Kawabata H, Kitano T, et al. Feasibility of salvage cord blood transplantation following fludarabine, melphalan and low-dose TBI for graft rejection after hematopoietic stem cell transplantation. Bone Marrow Transpl. 2016;51:985–7.CrossRef
6.
Zurück zum Zitat Sumi M, Shimizu I, Sato K, Ueki T, Akahane D, Ueno M, et al. Graft failure in cord blood transplantation successfully treated with short-term reduced-intensity conditioning regimen and second allogeneic transplantation. Int J Hematol. 2010;92:744–50.CrossRefPubMed Sumi M, Shimizu I, Sato K, Ueki T, Akahane D, Ueno M, et al. Graft failure in cord blood transplantation successfully treated with short-term reduced-intensity conditioning regimen and second allogeneic transplantation. Int J Hematol. 2010;92:744–50.CrossRefPubMed
7.
Zurück zum Zitat Mattsson J, Ringdén O, Storb R. Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2008;14(1Suppl 1):165–70.CrossRef Mattsson J, Ringdén O, Storb R. Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2008;14(1Suppl 1):165–70.CrossRef
8.
Zurück zum Zitat Koyama M, Hashimoto D, Nagafuji K, Eto T, Ohno Y, Aoyama K, et al. Expansion of donor-reactive host T cells in primary graft failure after allogeneic hematopoietic SCT following reduced-intensity conditioning. Bone Marrow Transpl. 2014;49:110–5.CrossRef Koyama M, Hashimoto D, Nagafuji K, Eto T, Ohno Y, Aoyama K, et al. Expansion of donor-reactive host T cells in primary graft failure after allogeneic hematopoietic SCT following reduced-intensity conditioning. Bone Marrow Transpl. 2014;49:110–5.CrossRef
9.
Zurück zum Zitat Georges G, Storb R. Failure of sustained engraftment: clinical manifestations and treatment. In: Atkinson K, editor. Clinical Bone Marrow and Blood Stem Cell Transplantation. 3rd ed. New York: Cambridge University Press; 2000. pp. 1088–188. Georges G, Storb R. Failure of sustained engraftment: clinical manifestations and treatment. In: Atkinson K, editor. Clinical Bone Marrow and Blood Stem Cell Transplantation. 3rd ed. New York: Cambridge University Press; 2000. pp. 1088–188.
10.
Zurück zum Zitat Storb R, Weiden PL, Sullivan KM, Appelbaum FR, Beatty P, Buckner CD, et al. Second marrow transplants in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin. Blood. 1987;70:116–21.PubMed Storb R, Weiden PL, Sullivan KM, Appelbaum FR, Beatty P, Buckner CD, et al. Second marrow transplants in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin. Blood. 1987;70:116–21.PubMed
11.
Zurück zum Zitat Nakasone H, Fuji S, Yakushijin K, Onizuka M, Shinohara A, Ohashi K, et al. Impact of total body irradiation on successful neutrophil engraftment in unrelated bone marrow or cord blood transplantation. Am J Hematol. 2017;92:171–8.CrossRefPubMed Nakasone H, Fuji S, Yakushijin K, Onizuka M, Shinohara A, Ohashi K, et al. Impact of total body irradiation on successful neutrophil engraftment in unrelated bone marrow or cord blood transplantation. Am J Hematol. 2017;92:171–8.CrossRefPubMed
12.
Zurück zum Zitat McCann SR, Bacigalupo A, Gluckman E, Hinterberger W, Hows J, Ljungman P, et al. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group. Bone Marrow Transpl. 1994;13:233–7. McCann SR, Bacigalupo A, Gluckman E, Hinterberger W, Hows J, Ljungman P, et al. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group. Bone Marrow Transpl. 1994;13:233–7.
13.
Zurück zum Zitat Deeg HJ, O’Donnell M, Tolar J, Agarwal R, Harris RE, Feig SA, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood. 2006;108:1485–91.CrossRefPubMedPubMedCentral Deeg HJ, O’Donnell M, Tolar J, Agarwal R, Harris RE, Feig SA, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood. 2006;108:1485–91.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Ohwada C, Nakaseko C, Ozawa S, Takeuchi M, Shono K, Koizumi M, et al. Second cord blood transplantation (CBT) with reduced-intensity conditioning for graft failure after the first CBT for AML. Bone Marrow Transpl. 2004;34:999–1000.CrossRef Ohwada C, Nakaseko C, Ozawa S, Takeuchi M, Shono K, Koizumi M, et al. Second cord blood transplantation (CBT) with reduced-intensity conditioning for graft failure after the first CBT for AML. Bone Marrow Transpl. 2004;34:999–1000.CrossRef
15.
Zurück zum Zitat Jabbour E, Rondon G, Anderlini P, Giralt SA, Couriel DR, Champlin RE, et al. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyteglobulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transpl. 2007;40:431–5.CrossRef Jabbour E, Rondon G, Anderlini P, Giralt SA, Couriel DR, Champlin RE, et al. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyteglobulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transpl. 2007;40:431–5.CrossRef
16.
Zurück zum Zitat Bolaños-Meade J, Luznik L, Muth M, Matsui WH, Huff CA, Smith BD, et al. Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transpl. 2009;43:477–80.CrossRef Bolaños-Meade J, Luznik L, Muth M, Matsui WH, Huff CA, Smith BD, et al. Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transpl. 2009;43:477–80.CrossRef
17.
Zurück zum Zitat Sanz GF, Saavedra S, Planelles D, Senent L, Cervera J, Barragán E, et al. Standardized unrelated donor cord blood transplantation in adults with hematologic malignancies. Blood. 2001;98:2332–8.CrossRefPubMed Sanz GF, Saavedra S, Planelles D, Senent L, Cervera J, Barragán E, et al. Standardized unrelated donor cord blood transplantation in adults with hematologic malignancies. Blood. 2001;98:2332–8.CrossRefPubMed
18.
Zurück zum Zitat Sanz J, Boluda JC, Martín C, González M, Ferrá C, Serrano D, et al. Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transpl. 2012;47:1287–93.CrossRef Sanz J, Boluda JC, Martín C, González M, Ferrá C, Serrano D, et al. Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transpl. 2012;47:1287–93.CrossRef
19.
Zurück zum Zitat Yamamoto H, Uchida N, Matsuno N, Kon A, Nishida A, Ota H, et al. I.v. BU/fludarabine plus melphalan or TBI in unrelated cord blood transplantation for high-risk hematological diseases. Bone Marrow Transpl. 2015;50:607–9.CrossRef Yamamoto H, Uchida N, Matsuno N, Kon A, Nishida A, Ota H, et al. I.v. BU/fludarabine plus melphalan or TBI in unrelated cord blood transplantation for high-risk hematological diseases. Bone Marrow Transpl. 2015;50:607–9.CrossRef
20.
Zurück zum Zitat Yamamoto H, Uchida N, Yuasa M, Kageyama K, Ota H, Kaji D, et al. A novel reduced-toxicity myeloablative conditioning regimen using full-dose busulfan, fludarabine, and melphalan for single cord blood transplantation provides durable engraftment and remission in nonremission myeloid malignancies. Biol Blood Marrow Transpl. 2016;22:1844–50.CrossRef Yamamoto H, Uchida N, Yuasa M, Kageyama K, Ota H, Kaji D, et al. A novel reduced-toxicity myeloablative conditioning regimen using full-dose busulfan, fludarabine, and melphalan for single cord blood transplantation provides durable engraftment and remission in nonremission myeloid malignancies. Biol Blood Marrow Transpl. 2016;22:1844–50.CrossRef
21.
Zurück zum Zitat Thiede C, Bornhauser M, Ehuinger G. Strategies and clinical implications of chimerism diagnosis after allogeneic hematopoietic stem cell transplantation. Acta Haematol. 2004;112:16–23.CrossRefPubMed Thiede C, Bornhauser M, Ehuinger G. Strategies and clinical implications of chimerism diagnosis after allogeneic hematopoietic stem cell transplantation. Acta Haematol. 2004;112:16–23.CrossRefPubMed
22.
Zurück zum Zitat Shimizu I, Kobayashi H, Nasu K, Otsuki F, Ueki T, Sumi M, et al. Successful engraftment of cord blood following a one-day reduced-intensity conditioning regimen in two patients suffering primary graft failure and sepsis. Bone Marrow Transpl. 2009;44:617–8.CrossRef Shimizu I, Kobayashi H, Nasu K, Otsuki F, Ueki T, Sumi M, et al. Successful engraftment of cord blood following a one-day reduced-intensity conditioning regimen in two patients suffering primary graft failure and sepsis. Bone Marrow Transpl. 2009;44:617–8.CrossRef
23.
Zurück zum Zitat Yamashita T, Sugimori C, Ishiyama K, Yamazaki H, Okumura H, Kondo Y, et al. Cord blood transplantation using minimum conditioning regimens for patients with hematologic malignancies complicated by severe infections. Int J Hematol. 2009;89:238–42.CrossRefPubMed Yamashita T, Sugimori C, Ishiyama K, Yamazaki H, Okumura H, Kondo Y, et al. Cord blood transplantation using minimum conditioning regimens for patients with hematologic malignancies complicated by severe infections. Int J Hematol. 2009;89:238–42.CrossRefPubMed
24.
Zurück zum Zitat Guardiola P, Kuentz M, Garban F, Blaise D, Reiffers J, Attal M, et al. Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation. Br J Haematol. 2000;111:292–302.CrossRefPubMed Guardiola P, Kuentz M, Garban F, Blaise D, Reiffers J, Attal M, et al. Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation. Br J Haematol. 2000;111:292–302.CrossRefPubMed
25.
Zurück zum Zitat Kanda J, Horwitz ME, Long GD, Gasparetto C, Sullivan KM, Chute JP, et al. Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2012;47:700–5.CrossRef Kanda J, Horwitz ME, Long GD, Gasparetto C, Sullivan KM, Chute JP, et al. Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2012;47:700–5.CrossRef
26.
Zurück zum Zitat Shimada K, Narimatsu H, Morishita Y, Kohno A, Saito S, Kato Y. Severe regimen-related toxicity of second transplantation for graft failure following reduced-intensity cord blood transplantation in an adult patient. Bone Marrow Transpl. 2006;37:787–8.CrossRef Shimada K, Narimatsu H, Morishita Y, Kohno A, Saito S, Kato Y. Severe regimen-related toxicity of second transplantation for graft failure following reduced-intensity cord blood transplantation in an adult patient. Bone Marrow Transpl. 2006;37:787–8.CrossRef
27.
Zurück zum Zitat Staba SL, Escolar ML, Poe M, Kim Y, Martin PL, Szabolcs P, et al. Cord-blood transplants from unrelated donors in patients with Hurler’s syndrome. N Engl J Med. 2004;350:1960–9.CrossRefPubMed Staba SL, Escolar ML, Poe M, Kim Y, Martin PL, Szabolcs P, et al. Cord-blood transplants from unrelated donors in patients with Hurler’s syndrome. N Engl J Med. 2004;350:1960–9.CrossRefPubMed
28.
Zurück zum Zitat Fujisaki G, Kami M, Kishi Y. Cord-blood transplants from unrelated donors in Hurler’s syndrome. N Engl J Med. 2004;351:506–7.CrossRefPubMed Fujisaki G, Kami M, Kishi Y. Cord-blood transplants from unrelated donors in Hurler’s syndrome. N Engl J Med. 2004;351:506–7.CrossRefPubMed
29.
Zurück zum Zitat Kusumi E, Kami M, Yuji K, Hamaki T, Murashige N, Hori A, et al. Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor. Bone Marrow Transpl. 2004;33:697–702.CrossRef Kusumi E, Kami M, Yuji K, Hamaki T, Murashige N, Hori A, et al. Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor. Bone Marrow Transpl. 2004;33:697–702.CrossRef
30.
Zurück zum Zitat Narimatsu H, Kami M, Miyakoshi S, Murashige N, Yuji K, Hamaki T, et al. Graft failure following reduced-intensity cord blood transplantation for adult patients. Br J Haematol. 2006;132:36–41.CrossRefPubMed Narimatsu H, Kami M, Miyakoshi S, Murashige N, Yuji K, Hamaki T, et al. Graft failure following reduced-intensity cord blood transplantation for adult patients. Br J Haematol. 2006;132:36–41.CrossRefPubMed
31.
Zurück zum Zitat Kawamura K, Kanda J, Fuji S, Murata M, Ikegame K, Yoshioka K, et al. Impact of the presence of HLA 1-locus mismatch and the use of low-dose antithymocyte globulin in unrelated bone marrow transplantation. Bone Marrow Transpl. 2017;52:1390–8.CrossRef Kawamura K, Kanda J, Fuji S, Murata M, Ikegame K, Yoshioka K, et al. Impact of the presence of HLA 1-locus mismatch and the use of low-dose antithymocyte globulin in unrelated bone marrow transplantation. Bone Marrow Transpl. 2017;52:1390–8.CrossRef
32.
Zurück zum Zitat Kanda J, Brazauskas R, Hu ZH, Kuwatsuka Y, Nagafuji K, Kanamori H, et al. Graft-versus-host disease rates after HLA-matched sibling bone marrow or peripheral blood hematopoietic cell transplantation: Comparison of North American Caucasian versus Japanese populations. Biol Blood Marrow Transpl. 2016;22:744–51.CrossRef Kanda J, Brazauskas R, Hu ZH, Kuwatsuka Y, Nagafuji K, Kanamori H, et al. Graft-versus-host disease rates after HLA-matched sibling bone marrow or peripheral blood hematopoietic cell transplantation: Comparison of North American Caucasian versus Japanese populations. Biol Blood Marrow Transpl. 2016;22:744–51.CrossRef
33.
Zurück zum Zitat Oh H, Loberiza FR Jr, Zhang MJ, Ringdén O, Akiyama H, Asai T, et al. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood. 2005;105:1408–16.CrossRefPubMed Oh H, Loberiza FR Jr, Zhang MJ, Ringdén O, Akiyama H, Asai T, et al. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood. 2005;105:1408–16.CrossRefPubMed
34.
Zurück zum Zitat Morishima Y, Kawase T, Malkki M, Morishima S, Spellman S, Kashiwase K, et al. Significance of ethnicity in the risk of acute graft-versus-host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2013;19:1197–203.CrossRef Morishima Y, Kawase T, Malkki M, Morishima S, Spellman S, Kashiwase K, et al. Significance of ethnicity in the risk of acute graft-versus-host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2013;19:1197–203.CrossRef
35.
Zurück zum Zitat Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK, et al. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transpl. 2009;15:704–17.CrossRef Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK, et al. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transpl. 2009;15:704–17.CrossRef
36.
Zurück zum Zitat Davies SM, Weisdorf DJ, Haake RJ, Kersey JH, McGlave PB, Ramsay NK, et al. Second infusion of bone marrow for treatment of graft failure after allogeneic bone marrow transplantation. Bone Marrow Transpl. 1994;14:73–7. Davies SM, Weisdorf DJ, Haake RJ, Kersey JH, McGlave PB, Ramsay NK, et al. Second infusion of bone marrow for treatment of graft failure after allogeneic bone marrow transplantation. Bone Marrow Transpl. 1994;14:73–7.
37.
Zurück zum Zitat Kuriyama K, Fuji S, Inamoto Y, Tajima K, Tanaka T, Inoue Y, et al. Impact of low dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation. Int J Hematol. 2016;103:453–60.CrossRefPubMed Kuriyama K, Fuji S, Inamoto Y, Tajima K, Tanaka T, Inoue Y, et al. Impact of low dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation. Int J Hematol. 2016;103:453–60.CrossRefPubMed
38.
Zurück zum Zitat Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855–64.CrossRefPubMed Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855–64.CrossRefPubMed
39.
Zurück zum Zitat Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117:3214–9.CrossRefPubMedPubMedCentral Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117:3214–9.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Yang F, Lu D, Hu Y, Huang X, Huang H, Chen J, et al. Risk factors for graft-versus-host disease after transplantation of hematopoietic stem cells from unrelated donors in the China marrow donor program. Ann Transpl. 2017;22:384–401.CrossRef Yang F, Lu D, Hu Y, Huang X, Huang H, Chen J, et al. Risk factors for graft-versus-host disease after transplantation of hematopoietic stem cells from unrelated donors in the China marrow donor program. Ann Transpl. 2017;22:384–401.CrossRef
41.
Zurück zum Zitat Ozawa S, Nakaseko C, Nishimura M, Maruta A, Cho R, Ohwada C, et al. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program. Br J Haematol. 2007;137:142–51.CrossRefPubMed Ozawa S, Nakaseko C, Nishimura M, Maruta A, Cho R, Ohwada C, et al. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program. Br J Haematol. 2007;137:142–51.CrossRefPubMed
Metadaten
Titel
Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen
verfasst von
Takumi Hoshino
Satoru Takada
Nahoko Hatsumi
Toru Sakura
Publikationsdatum
08.02.2019
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 4/2019
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-019-02610-4

Weitere Artikel der Ausgabe 4/2019

International Journal of Hematology 4/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.